AM0010-301: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen

Principal Investigator

Charles Lopez

Study Purpose

The purpose of this study is to evaluate the efficacy and safety of the study drug, AM0010, in combination with FOLFOX versus FOLFOX alone in patients with advanced metastatic pancreatic cancer.

Medical Condition(s)

Advanced Metastatic Pancreatic Cancer

Eligibility Criteria

≥ 18 years of age
metastatic pancreatic cancer
Previously treated with first-line gemcitabine containing regimen

Age Range

18 - 100

Healthy Volunteers Needed


Duration of Participation

You will receive FOLFOX for up to 6 months. You will receive the study drug until your disease progresses, you can’t tolerate the treatment, or you and/or your doctor decide to stop treatment.
After you finish treatment your doctor will continue to watch you for side effects and follow your condition until study completion.

Minors Included



OHSU Knight Cancer Institute Information line 503-494-1080


ARMO BioSciences

Recruitment End


Compensation Provided


Go Back